Jubilant Ingrevia reports FY26 revenue and profit growth
after close1 source ↓written by the desknot a recommendation
Jubilant Ingrevia reported year-over-year revenue growth and net profit increase for FY26, driven by strong results in Speciality Chemicals. The company expanded its portfolio with the acquisition of Remidex Pharma and navigated regulatory changes, including a one-time labour code expense. This performance may enhance investor sentiment in the sector.
Not investment advice. For informational purposes only.